Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
LeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares IssuedShares OutstandingShares Outstanding
Ratios

ArriVent BioPharma (AVBP) Shares Outstanding (2023 - 2026)

ArriVent BioPharma has reported Shares Outstanding over the past 4 years, most recently at $45.3 million for Q1 2026.

  • Quarterly results put Shares Outstanding at $45.3 million for Q1 2026, up 33.1% from a year ago — trailing twelve months through Mar 2026 was $45.3 million (up 33.1% YoY), and the annual figure for FY2025 was $42.5 million, up 25.95%.
  • Shares Outstanding reached $45.3 million in Q1 2026 per AVBP's latest filing, up from $42.5 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $45.3 million in Q1 2026 and bottomed at $2.6 million in Q2 2023.
  • Median Shares Outstanding over the past 4 years was $33.7 million (2024), compared with a mean of $26.6 million.
  • The largest annual shift saw Shares Outstanding skyrocketed 1187.12% in 2024 before it increased 1.63% in 2025.
  • Over 4 years, Shares Outstanding stood at $2.7 million in 2023, then soared by 1127.72% to $33.7 million in 2024, then grew by 25.95% to $42.5 million in 2025, then increased by 6.73% to $45.3 million in 2026.
  • Business Quant data shows Shares Outstanding for AVBP at $45.3 million in Q1 2026, $42.5 million in Q4 2025, and $40.9 million in Q3 2025.